TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04309461

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Control
Description: The Stress Management Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target stress, relaxation, and sleep. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. The Stress Management Program, including the use of the app and assessments, is identical to the Adapted MBC2 program, with the exception of the content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted MBC2 Program
Description: The Adapted MBC2 Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target fruit and vegetable intake, dietary fat intake, physical activity, and high sedentary leisure screen time. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor goal thermometers to meet targets.
Study: NCT04586426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered by SC injection.
Study: NCT00981851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium (Spiriva) + Salbutamol (Ventolin)
Description: 1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer. cigarette smoking

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 time inhalation of placebo with the amount of puffs similar to the active comparator. cigarette smoking
Study: NCT04403074

Intervention type: PROCEDURE
Intervention: Celiac Plexus Neurolysis
Description: When CPBs are not effective (less than one month of relief) then a Celiac Plexus Neurolysis may be completed to manage pain associated with Chronic Pancreatitis.
Study: NCT04630808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCX 470 0.1%
Description: NCX 470 Ophthalmic Solution, 0.1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005%
Description: Latanoprost Ophthalmic Solution, 0.005%
Study: NCT00595985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib 400mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Study: NCT01847339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the saline solution and then will be placed by the surgeon in the epidural space before final closure
Study: NCT03098238

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological sample
Description: Biological sampling of two citrate tubes (18 ml) during a normal blood

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological sample
Description: Biological sampling of two citrate tubes (18 ml) during a normal blood
Study: NCT02042391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab sc consolidation
Description: Patients considered low-risk will receive four more single therapeutic agent applications of rituximab administered subcutaneously at a fixed dose of 1400 mg once every three weeks at days 50, 71, 92 and 113.
Study: NCT06023134

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography will be used for specific right ventricular measurements or findings: TAPSE, TAPSE:PASP ratio, tissue Doppler velocity at lateral tricuspid annulus, fractional area change, right ventricular strain, right ventricular hypertrophy, right atrial size, volumes, ejection fraction, tricuspid and pulmonary regurgitation, inferior vena cava diameter and collapsibility, shift of interventricular septum, further assisting the diagnosis of RHF.
Study: NCT02042391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab sc combined with CHOP chemotherapy
Description: Patients considered high-risk will receive four more applications of rituximab administered subcutaneously at a fixed dose of 1400 mg combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113. CHOP chemotherapy will be administered at standard doses: cyclophosphamide 750 mg/m2, adriamycine 50 mg/m2, vincristine 1.4mg/m2 (maximum total dose: 2mg) and prednisone 100mg (at day 1 to 5 of each cycle). Cyclophosphamid, adriamycine and vincristine will be infused intravenously. Prednison will be administered orally in a single dose. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx
Description: Patients considered very high-risk will receive six more applications of rituximab sc at a fixed dose of 1400 mg combined with chemotherapy every 3 weeks. Chemotherapy is CHOP at days 50, 92 and 134 (cyclophosphamide IV 750 mg/m2, adriamycine IV 50 mg/m2, vincristine IV 1.4mg/m2 (maximum total dose: 2mg) and prednisone PO 100mg (at day 1 to 5 of each cycles). Chemotherapy is DHAOx at days 71, 113 and 155 (oxaliplatin (130 mg/m2, day 1) and cytarabine (ARA-C, 2x 1000 mg/m2 at day 2) dexamethasone PO (40 mg/m2, day 1)), as per institutional practice. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
Study: NCT02459054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SynCardia 50cc temporary Total Artificial Heart (TAH-t)
Description: Replacement of both ventricles and all four valves with the investigational device as a bridge to transplantation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SynCardia 50cc temporary Total Artificial Heart (TAH-t)
Description: Replacement of both ventricles and all four valves with the investigational device as a bridge to transplantation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SynCardia 50cc temporary Total Artificial Heart (TAH-t)
Description: Replacement of both ventricles and all four valves with the investigational device as a bridge to transplantation.
Study: NCT03551249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused ultrasound (FUS)
Description: FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
Study: NCT03098238

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological sample
Description: Biological sampling of two citrate tubes (18 ml) during a normal blood
Study: NCT06023134

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography will be used for specific right ventricular measurements or findings: TAPSE, TAPSE:PASP ratio, tissue Doppler velocity at lateral tricuspid annulus, fractional area change, right ventricular strain, right ventricular hypertrophy, right atrial size, volumes, ejection fraction, tricuspid and pulmonary regurgitation, inferior vena cava diameter and collapsibility, shift of interventricular septum, further assisting the diagnosis of RHF.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography will be used for specific right ventricular measurements or findings: TAPSE, TAPSE:PASP ratio, tissue Doppler velocity at lateral tricuspid annulus, fractional area change, right ventricular strain, right ventricular hypertrophy, right atrial size, volumes, ejection fraction, tricuspid and pulmonary regurgitation, inferior vena cava diameter and collapsibility, shift of interventricular septum, further assisting the diagnosis of RHF.
Study: NCT02487498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 capsules for inhalation, delivered via QVA149 SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol
Description: Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (umeclidinium/vilanterol )
Description: Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (QVA149)
Description: Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
Study: NCT02014818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoCr-EES

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoCr-EES
Study: NCT06023134

Intervention type: DIAGNOSTIC_TEST
Intervention: Right heart catheterization
Description: Right heart catheterization is the gold standard for the diagnosis of PH. It also allows for direct measurement of intracardiac and pulmonary pressures, as well as cardiac output, and is commonly used to estimate right ventricular preload and afterload.

Intervention type: DIAGNOSTIC_TEST
Intervention: Right heart catheterization
Description: Right heart catheterization is the gold standard for the diagnosis of PH. It also allows for direct measurement of intracardiac and pulmonary pressures, as well as cardiac output, and is commonly used to estimate right ventricular preload and afterload.

Intervention type: DIAGNOSTIC_TEST
Intervention: Right heart catheterization
Description: Right heart catheterization is the gold standard for the diagnosis of PH. It also allows for direct measurement of intracardiac and pulmonary pressures, as well as cardiac output, and is commonly used to estimate right ventricular preload and afterload.
Study: NCT04294992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: Study drugs will be prepared, diluted to a volume of 10 mL using saline 0.9%
Study: NCT03691311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Description: Two injections on days 1 and 8 previous to surgery breast cancer excision
Study: NCT03834974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun Safety Social Media Challenge
Description: Participants will attend a webinar to learn how to create effective social media posts about sun safety and be oriented to the social media accounts on which the messages will be posted. They will be informed that posts should include a sun safety message (e.g., promoting sunscreen use and protective clothing/hats or discouraging risk behaviors like tanning and burning). They will be encouraged to be creative so that the message gets likes and shares. Participants will be encouraged to follow the feeds to see the engagement on their posts, to share the posts in their feed, and to see other participants' posts. Participants will receive a $10 Amazon gift card per post for a maximum of 6 posts ($60). The participant who created the post that receives the most likes, comments, and shares each week will win a $50 Amazon gift card.
Study: NCT04294992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8mg
Description: Study drugs will be prepared, diluted to a volume of 10 mL using saline 0.9%
Study: NCT06072404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OxigenOzone_Insufflation
Description: intra-tissutal perialveolar injections of a 15-mL mixture of OxigenOzone (O2O3) with a 26Gx 1⁄2 - 0.45x13 mm needle and insufflation of the same mixture in the post-extraction site for at least 1 minute, hemostasis, and suture.
Study: NCT02000830

Intervention type: DRUG
Intervention: Stannsoporfin
Description: Stannsoporfin administered by intramuscular (IM) injection

Intervention type: DRUG
Intervention: Stannsoporfin
Description: Stannsoporfin administered by intramuscular (IM) injection
Study: NCT03834974

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Health Social Media Challenge
Description: Participants will attend a webinar to learn how to create effective social media posts about using technology to get healthy and be oriented to the social media accounts on which the messages will be posted. They will be informed that posts should mention some way that technology (e.g., mobile apps, wearables) can be used to promote a healthy habit (e.g., diet, exercise). They will be encouraged to be creative so that the message gets likes and shares. Participants will be encouraged to follow the feeds to see the engagement on their posts, to share the posts in their feed, and to see other participants' posts. Participants will receive a $10 Amazon gift card per post for a maximum of 6 posts ($60). The participant who created the post that receives the most likes, comments, and shares each week will win a $50 Amazon gift card.
Study: NCT02830113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal treatment
Description: One session of complete scaling, polishing, root planning, and the irrigation of periodontal pockets with a 10% povidone iodine solution
Study: NCT04828213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion Treatment with Tooth-borne RME appliance (Hyrax)
Description: The patients were treated with a expansion appliance containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion Treatment with Tooth-borne RME appliance (Hyrax)
Description: The patients were treated with a expansion appliance containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion Treatment with Hybrid hyrax RME appliance
Description: The patients were treated with a Hybrid hyrax RME appliance containing a Hyrax expansion screw positioned parallel to the second premolars and mini-screws. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion Treatment with Hybrid hyrax RME appliance
Description: The patients were treated with a Hybrid hyrax RME appliance containing a Hyrax expansion screw positioned parallel to the second premolars and mini-screws. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.
Study: NCT04150211

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyherbal Exten(d) vs Placebo
Description: Supplementation during 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Polyherbal Exten(d) vs Placebo
Description: Supplementation during 4 weeks
Study: NCT03411980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Single oral dose (1 x 2 mg immediate-release, film-coated tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Single oral dose (1 x 2 mg immediate-release, film-coated tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Single oral dose (1 x 2 mg immediate-release, film-coated tablet)
Study: NCT01065870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant gemcitabine, capecitabine, and docetaxel
Description: 6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.~Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.~Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, capecitabine, docetaxel followed by radiotherapy
Description: 6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.~Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.~Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment.~Radiotherapy should start 2 to 3 weeks after last planned dose of GTX. Gemcitabine at 750mg/M2 days 5, 12, 26, 33 along with capecitabine 1000 mg bid for 5 days darbepoetin 200ug, every 2 weeks if the hemoglobin is less than 10.5 gms/dl while undergoing radiotherapy.~Pegfiligastrim 6mg at the end of week 2 if the WBC count is less than 2500 cells/cu mm.
Study: NCT00177853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Patients will start celecoxib (200mg PO BID) beginning 3-5 days prior to chemoradiation at home and receive the drug until 30 days following the completion of chemoradiation.
Study: NCT02524379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: 3 day drug regimen beginning 8 hours after acute traumatic spinal cord injury.
Study: NCT00177853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Preoperative chemoradiation will consist of escalating doses of irinotecan (30 50 mg/m2 IV) once weekly for a total of 4 doses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: concurrent radiotherapy
Description: 50.4 cGy of standard external beam radiation. The radiation will be given in 28 treatments of 1.8 cGy per treatment over 5.5 weeks. This will be given in an outpatient setting.
Study: NCT03481101

Intervention type: DEVICE
Group type: OTHER
Intervention: PET/CT
Description: 3 extra scans with FDG-PET/CT and 4 blood samples
Study: NCT03211780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: General Electric LOGIQ E9 ultrasound system
Description: Patients will be brought to the operating room in line with standard clinical practice and after esophageal exposure, but before surgical mobilization of the esophagus, shear wave vibrometry and B-mode imaging will be performed after esophageal distension with a fluid filled balloon intra-operatively.
Study: NCT04619329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GSMs-TACE
Description: TACE using Lobaplatin (30-40mg/m2) and gelatin sponge microspheres (150-350μm, 350-560μm, 560-710μm or 710-1000μm)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical Resection of HCC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Resection
Description: Surgical Resection of HCC
Study: NCT01704690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 and Paclitaxel
Description: S-1 and Paclitaxel are used in the S-1 and Paclitaxel arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and Cisplatin
Description: The paclitaxel and cisplatin combination will be used in the Paclitaxel and Cisplatin arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU and Cisplatin
Description: The cisplatin and 5-fluorouracil combination will be used in the Cisplatin and 5-FU arm.
Study: NCT03815799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Erector Spinae Block
Description: A linear ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. 40 ml bupivacaine/lidocaine mixture will be injected into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Standard perioperative and postoperative analgesia protocol will be given consisting of paracetamol 1 gr IV and tenoxicam 20 mg IV initiated after induction of anesthesia. At the end of the operation patients will receive meperidine 0.5 mg/kg IV before extubation. Postoperative pain levels will be determined by Numeric Rating Scale (NRS) system, 20 minutes intervals in the first hour and at 2th, 6th, 12th and 24 th hour. For the first hour in the postoperative care unit, tramadol 50 mg IV will be given for rescue analgesia with minimum 20 minutes between doses, in patients showing a NRS ≥ 4. Paracetamol 1 g / 12 hour will be given during ward follow-up. In the ward in patients showing a NRS ≥ 4 tramadol 50 mg IV will be given for analgesia.
Study: NCT04523038

Intervention type: DIAGNOSTIC_TEST
Intervention: S-Albumin
Description: Preoperative serum albumin levels

Intervention type: DIAGNOSTIC_TEST
Intervention: S-Albumin
Description: Preoperative serum albumin levels